ArticleEuropean journal of haematology2026
Bone Marrow Pathology in Cold Agglutinin-Mediated Autoimmune Hemolytic Anemia: A Study of 56 Cases.
Article in European journal of haematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Cold agglutinin disease.British journal of haematology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cold agglutinin disease (CAD) is a rare form of autoimmune hemolytic anemia (AIHA). CAD occurs in the context of a small clonal B-cell lymphoproliferation restricted to blood and/or bone marrow (BM), without overt or extramedullary lymphoma. The WHO-HAEM5 introduced a description of the CAD-associated lymphoproliferative disorder (CAD-LPD) in the BM as a desirable criterium for CAD. Still, data on BM pathology underlying CAD remain scarce. We assessed the clinical and pathologic characteristics of a large patient cohort with cold-type AIHA. A total of 85 BM biopsies of 56 patients were evaluated. In 10 patients (18%), pathology revision revealed other overt B-cell malignancies leading to a diagnosis of cold agglutinin syndrome. In the remaining 46, evidence for B-cell clonality was found in the vast majority (45; 98%), manifesting as a paraproteinemia and/or clonal B-cells or plasma cells in BM. Most of these 45 had an M-protein (89%), evidence of monoclonal B-cells and/or plasma cells in BM tissue (89%), and were MYD88 wild-type (100%). Surprisingly, while ancillary methods detected clonality in the majority (84%), only 5 (11%) of 45 CAD cases strictly fulfilled the WHO-HAEM5 morphological description for CAD-LPD. These data imply that sensitive techniques should be used in BM evaluation in CAD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.